In this issue of the Journal of Clinical Investigation, Anil Sood and colleagues at M.D. Anderson Cancer Center identified a cellular membrane protein, ATP11B, that mediates cisplatin resistance in ovarian cancer cells. They found that ATP11B expression was correlated with higher tumor grade in human ovarian cancer samples and with cisplatin-resistance in human ovarian cancer cell lines. Further, loss of ATP11B restored the sensitivity of ovarian cancer cell lines to cisplatin and reduced ovarian tumor growth in mice. These findings suggest that ATP11B could serve as a therapeutic target to overcome cisplatin resistance.
TITLE: ATP11B mediates platinum resistance in ovarian cancer cells
View this article at: http://www.jci.org/articles/view/65425?key=1b568a84b2ed6f3104ee
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
Journal of Clinical Investigation. "Gene Identified That Mediates Cisplatin Resistance In Ovarian Cancer." Medical News Today. MediLexicon, Intl., 17 Apr. 2013. Web.
26 Aug. 2016. <http://www.medicalnewstoday.com/releases/259123.php>
Journal of Clinical Investigation. (2013, April 17). "Gene Identified That Mediates Cisplatin Resistance In Ovarian Cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.